HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ThermaCare HeatWraps Recall Is Second In Seven Months By Pfizer

Executive Summary

Pfizer Consumer Healthcare division recalls one lot of ThermaCare Back Pain Therapy HeatWraps, up to 16HR pain relief, because the products could include cells that have a higher cell temperature than specified. Firm in late 2018 recalled six lots of ThermaCare HeatWraps Muscle Joint Therapy 8-hour strength due to reports of leaking heat cells.

You may also be interested in...



GSK And Pfizer Agree To Divest ThermaCare To Win EU Approval For JV

GSK and Pfizer must find a buyer for the global rights to the ThermaCare pain relief brand to receive European Commission approval for their proposed joint venture.

Leaking Heat Cells In Pfizer's ThermaCare HeatWraps Prompt Recall

Firm's consumer health division extends to consumer level a recall it advised retailers and distributors about on Oct. 2 because products from the six lots have a potential to leak ingredients contained in heat cell wraps. A leaking heat cell in a HeatWrap could cause skin injuries such as burns, blisters or skin irritation on the applied areas.

Symptoms Change But Savings OTC Drugs Deliver For US Health Care Spending Continue Growing

Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS148764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel